Advertisement

Breast Cancer Research

, 16:P44 | Cite as

PB.40. What happens to the ductal carcinoma in situ in HER2-positive cancers treated with neoadjuvant chemotherapy and trastuzumab?

  • R Millican-Slater
  • D Dodwell
  • K Horgan
  • M Mcmahon
  • B Dall
  • N Sharma
Open Access
Poster presentation
  • 523 Downloads

Keywords

Breast Cancer Trastuzumab Taxane Anthracycline Invasive Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Introduction

There are few data regarding the effect of neoadjuvant chemotherapy (NACT) and trastuzumab on any ductal carcinoma in situ (DCIS) associated with the HER2-positive invasive carcinoma. HER2-positive breast cancers are more likely to achieve a pathological complete response (defined as absence of invasive tumour in the final excision specimen allowing for the presence of DCIS). We review our data to see what happens to HER2-positive DCIS associated with HER2-positive invasive cancer treated with NACT.

Methods

All cases that were HER2-positive from our local NACT database were identified from 2010 to 2012. The imaging features, core biopsy and final histology were documented

Results

A total 41 of 150 patients that received NACT (anthracycline and taxane based) were HER2-positive and treated with trastuzumab. In total, 40/41 cases had surgery following neoadjuvant treatment, 24/41 (59%) cases had calcifications on mammography, and 21/41 (51%) obtained a pCR. Of the 24 cases with calcification, 14 (44%) had a pCR with 9/14 (29%) having residual DCIS. Seven of 24 cases had a WLE in which the calcifications on mammography were unchanged in extent or appearance. A total 17/41 were without calcification, seven (57%) had a pCR with 2/7 (62%) having residual DCIS that was noncalcified.

Conclusion

pCR is higher in the HER2-positive group compared with the HER2-negative group (51% vs. 20%). In total, 48% achieved a pCR with no residual DCIS but 52% still had residual DCIS, suggesting that trastuzumab may be less effective in treating HER2-positive DCIS.

Copyright information

© Millican-Slater et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  • R Millican-Slater
    • 1
  • D Dodwell
    • 1
  • K Horgan
    • 1
  • M Mcmahon
    • 1
  • B Dall
    • 1
  • N Sharma
    • 1
  1. 1.Leeds Teaching Hospital NHS TrustLeedsUK

Personalised recommendations